Vicente Climent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1130795/publications.pdf

Version: 2024-02-01

147566 123241 4,016 100 31 61 citations h-index g-index papers 114 114 114 5310 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal, 2004, 25, 1880-1890.	1.0	532
2	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	1.2	340
3	Anatomic Relations Between the Esophagus and Left Atrium and Relevance for Ablation of Atrial Fibrillation. Circulation, 2005, 112, 1400-1405.	1.6	284
4	The architecture of the left lateral atrial wall: a particular anatomic region with implications for ablation of atrial fibrillation. European Heart Journal, 2008, 29, 356-362.	1.0	249
5	How Close Are the Phrenic Nerves to Cardiac Structures? Implications for Cardiac Interventionalists. Journal of Cardiovascular Electrophysiology, 2005, 16, 309-313.	0.8	239
6	The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cellular and Molecular Life Sciences, 2013, 70, 121-136.	2.4	148
7	Current Epidemiology and Outcome of Infective Endocarditis. Medicine (United States), 2015, 94, e1816.	0.4	129
8	Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. Stroke, 2003, 34, 1181-1186.	1.0	93
9	Morphological evidence of muscular connections between contiguous pulmonary venous orifices: Relevance of the interpulmonary isthmus for catheter ablation in atrial fibrillation. Heart Rhythm, 2009, 6, 1192-1198.	0.3	86
10	Anatomic evaluation of the left phrenic nerve relevant to epicardial and endocardial catheter ablation: Implications for phrenic nerve injury. Heart Rhythm, 2009, 6, 764-768.	0.3	83
11	Serum Levels of High-Sensitivity Troponin T: A Novel Marker for Cardiac Remodeling in Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2010, 16, 950-956.	0.7	82
12	Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart, 2004, 90, 1162-1166.	1.2	80
13	Morphological changes in the normal pattern of ventricular myoarchitecture in the developing human heart. The Anatomical Record, 1995, 243, 483-495.	2.3	74
14	Infective Endocarditis in Patients With Bicuspid Aortic Valve or MitralÂValveÂProlapse. Journal of the American College of Cardiology, 2018, 71, 2731-2740.	1.2	65
15	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	1.2	59
16	Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1682-1699.	1.2	55
17	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Journal of the American Heart Association, 2016, 5, .	1.6	53
18	Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients. European Journal of Heart Failure, 2006, 8, 621-627.	2.9	49

#	Article	IF	CITATIONS
19	A Contemporary Picture of Enterococcal Endocarditis. Journal of the American College of Cardiology, 2020, 75, 482-494.	1.2	49
20	ASK1 Overexpression Accelerates Paraquat-Induced Autophagy via Endoplasmic Reticulum Stress. Toxicological Sciences, 2011, 119, 156-168.	1.4	48
21	Morphology and significance of programmed cell death in the developing limb bud of the vertebrate embryo. Microscopy Research and Technique, 1996, 34, 236-246.	1.2	45
22	Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. European Journal of Heart Failure, 2005, 7, 1168-1170.	2.9	45
23	Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. European Journal of Internal Medicine, 2012, 23, 169-174.	1.0	45
24	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
25	Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort. Clinical Infectious Diseases, 2019, 69, 1690-1700.	2.9	44
26	Role of age and comorbidities in mortality of patients with infective endocarditis. European Journal of Internal Medicine, 2019, 64, 63-71.	1.0	43
27	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. International Journal of Cardiology, 2017, 248, 232-238.	0.8	41
28	Induction of cardiogenesis by Hensen's node and fibroblast growth factors. Cell and Tissue Research, 2002, 309, 237-249.	1.5	40
29	G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Toxicology, 2014, 324, 1-9.	2.0	40
30	Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosisâ€"The ESCAPE Study. Clinical Infectious Diseases, 2018, 66, 825-832.	2.9	40
31	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. Journal of Cardiac Failure, 2008, 14, 414-419.	0.7	33
32	Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart, 2007, 93, 957-962.	1.2	28
33	Infective endocarditis in patients with cancer. Medicine (United States), 2017, 96, e7913.	0.4	28
34	Mutations in <i>TRIM63</i> cause an autosomal-recessive form of hypertrophic cardiomyopathy. Heart, 2020, 106, 1342-1348.	1.2	27
35	Morphological analysis of the fish heart ventricle: Myocardial and connective tissue architecture in teleost species. Annals of Anatomy, 1995, 177, 267-274.	1.0	23
36	Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. International Journal of Clinical Practice, 2009, 63, 1465-1471.	0.8	23

3

#	Article	IF	CITATIONS
37	The MAPK1/3 pathway is essential for the deregulation of autophagy observed in G2019S LRRK2 mutant fibroblasts. Autophagy, 2012, 8, 1537-1539.	4.3	23
38	Effects of Exergaming in Patients with Cardiovascular Disease Compared to Conventional Cardiac Rehabilitation: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 3492.	1.2	23
39	Effects of Pretreatment with Intravenous Flecainide on Efficacy of External Cardioversion of Persistent Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 368-372.	0.5	21
40	Growth Hormone Therapy and the Heart. American Journal of Cardiology, 2006, 97, 1097-1102.	0.7	21
41	Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis. Journal of Infection and Chemotherapy, 2018, 24, 555-562.	0.8	21
42	Pharmacologic Therapy in Growth Hormone Disorders and the Heart. Current Medicinal Chemistry, 2007, 14, 1399-1407.	1.2	20
43	Early Morphologic Changes Following Microwave Endocardial Ablation for Treatment of Chronic Atrial Fibrillation During Mitral Valve Surgery. Journal of Cardiovascular Electrophysiology, 2004, 15, 1277-1283.	0.8	19
44	Predictores de riesgo en una cohorte española con cardiolaminopatÃas. Registro REDLAMINA. Revista Espanola De Cardiologia, 2021, 74, 216-224.	0.6	19
45	PINK1 deficiency enhances autophagy and mitophagy induction. Molecular and Cellular Oncology, 2016, 3, e1046579.	0.3	18
46	Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017). Mayo Clinic Proceedings, 2021, 96, 132-146.	1.4	17
47	Sinus node structural changes in patients with long-standing chronic atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1394-1395.	0.4	16
48	Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thrombosis Research, 2010, 126, e46-e50.	0.8	16
49	Capillary Supply to the Sinus Node in Subjects with Long-Term Atrial Fibrillation. Annals of Thoracic Surgery, 2010, 89, 38-43.	0.7	16
50	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLoS ONE, 2015, 10, e0125164.	1.1	15
51	Low QRS voltage in cardiac tamponade: a study of 70 cases. International Journal of Cardiology, 2002, 83, 91-92.	0.8	14
52	Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 613-621.	0.2	14
53	Left-sided infective endocarditis in patients with liver cirrhosis. Journal of Infection, 2015, 71, 627-641.	1.7	14
54	Prevalence and clinical outcomes of dystrophinâ€associated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	2.9	14

#	Article	IF	Citations
55	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. International Journal of Cardiology, 2009, 132, 227-232.	0.8	13
56	Combination of late gadolinium enhancement and genotype improves prediction of prognosis in nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1183-1196.	2.9	13
57	Soluble TNF- \hat{l}_{\pm} and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels. European Journal of Heart Failure, 2004, 6, 877-882.	2.9	12
58	Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failureâ ⁺ 1. European Journal of Echocardiography, 2006, 7, 45-52.	2.3	12
59	Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations. Current Medicinal Chemistry, 2010, 17, 1679-1689.	1.2	11
60	CaracterÃsticas clÃnicas y pronóstico de la enfermedad de Danon. Análisis del registro multicéntrico español. Revista Espanola De Cardiologia, 2019, 72, 479-486.	0.6	11
61	Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment. Minerva Endocrinologica, 2019, 44, 159-168.	1.7	11
62	The status of farmed fish hearts: an alert to improve health and production in three Mediterranean species. Reviews in Fish Biology and Fisheries, 2012, 22, 779-789.	2.4	10
63	Severe sleep apnea–hypopnea syndrome is related to left ventricle dysfunction and hypertrophy in acromegalic patients. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2015, 62, 366-372.	0.8	10
64	Infective endocarditis in elderly and very elderly patients. Aging Clinical and Experimental Research, 2020, 32, 1383-1388.	1.4	9
65	Atrial stunning as predictor of early relapse into atrial fibrillation after cardioversion. International Journal of Cardiology, 2006, 110, 427-428.	0.8	8
66	Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry. General Thoracic and Cardiovascular Surgery, 2019, 67, 585-593.	0.4	8
67	NT-proBNP Levels and Hypertension. Their Importance in the Diagnosis of Heart Failure. Revista Espanola De Cardiologia (English Ed), 2004, 57, 396-402.	0.4	7
68	Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish Collaboration on Endocarditis (GAMES) experience. Journal of Antimicrobial Chemotherapy, 2019, 74, 1713-1717.	1.3	7
69	Hipertensión y valores de NT-proBNP. Su importancia en el diagnóstico de insuficiencia cardÃaca. Revista Espanola De Cardiologia, 2004, 57, 396-402.	0.6	7
70	Short- and long-term effects of growth hormone on the heart. International Journal of Cardiology, 2008, 124, 393-394.	0.8	6
71	Effects of atorvastatin 80Âmg daily on indices of matrix remodelling in †high-risk' patients with ischemic heart disease. International Journal of Cardiology, 2010, 139, 95-97.	0.8	6
72	Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches. Annals of Medicine, 2013, 45, 341-347.	1.5	6

#	Article	IF	Citations
73	Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker. Orphanet Journal of Rare Diseases, 2019, 14, 170.	1.2	6
74	Maximum Longitudinal Relaxation Velocity of the Left Ventricle: Its Clinical Value and Relationship with NT-proBNP Plasma Levels in Heart Failure. Echocardiography, 2006, 23, 295-302.	0.3	5
75	Oxidative damage is present in plasma and circulating neutrophils 4Âweeks after a high mountain expedition. European Journal of Applied Physiology, 2012, 112, 2923-2932.	1.2	5
76	Involvement of the â^'420C>G <i><scp>RETN</scp></i> polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy. Journal of Internal Medicine, 2015, 278, 50-58.	2.7	5
77	Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy. Medicina ClÃnica, 2019, 153, 47-55.	0.3	5
78	Fractional shortening-velocity ratio for assessment of aortic stenosis severity in patients with systolic dysfunction. International Journal of Cardiology, 2003, 92, 229-234.	0.8	4
79	Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?. Journal of Thrombosis and Thrombolysis, 2006, 21, 163-166.	1.0	4
80	Cardiovascular risk factors: Is the metabolic syndrome related to aging? Epidemiology in a Portuguese population. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 885-891.	1.8	4
81	Anticoagulant Therapy Modifies Fibrinolytic Dysfunction in Chronic Atrial Fibrillation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 219-224.	0.5	3
82	Heart valve disease in acromegaly. International Journal of Cardiology, 2003, 90, 331-332.	0.8	3
83	Antiplatelet versus anticoagulant therapies in advanced age: An unfinished task. International Journal of Cardiology, 2006, 110, 271-272.	0.8	3
84	Valor pronóstico de los niveles séricos del factor de necrosis tumoral alfa en pacientes con insuficiencia cardíaca. Revista Espanola De Cardiologia, 2003, 56, 160-167.	0.6	3
85	Clinical Experience With Levosimendan in the Emergency Department of a Tertiary Care Hospital. Revista Espanola De Cardiologia (English Ed), 2007, 60, 878-882.	0.4	2
86	Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2021, 14, 948-950.	1.1	2
87	Growth Hormone Therapy, Is it Always Good for the Heart?. European Heart Journal, 2004, 25, 183.	1.0	1
88	Gadolinium-Enhanced Cardiovascular Magnetic Resonance and Exercise Capacity in Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 853-860.	0.4	1
89	Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy. European Journal of Clinical Investigation, 2016, 46, 123-129.	1.7	1
90	Galectin-3 and \hat{l}^2 -trace protein concentrations are higher in clinically unaffected patients with Fabry disease. Scientific Reports, 2019, 9, 6235.	1.6	1

#	Article	IF	CITATIONS
91	Effects of endocardial microwave energy ablation. Indian Pacing and Electrophysiology Journal, 2005, 5, 233-43.	0.3	1
92	Prothrombin fragment F1+2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples. International Journal of Cardiology, 2002, 83, 289-290.	0.8	0
93	Matrix metalloproteinases in atrial fibrillation. Journal of the American College of Cardiology, 2004, 43, 152.	1.2	0
94	Laser deposition of stainless and tool steel on a copper-beryllium alloy for plastic injection mould improvement. , 2006, , .		0
95	Severe sleep apnea–hypopnea syndrome is related to left ventricle dysfunction and hypertrophy in acromegalic patients. EndocrinologÃa Y Nutrición (English Edition), 2015, 62, 366-372.	0.5	0
96	La importancia de la estratificación de riesgo de muerte súbita en la miocardiopatÃa hipertrófica. Revista Espanola De Cardiologia, 2015, 68, 544.	0.6	0
97	Importance of Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2015, 68, 544.	0.4	0
98	Arrythmogenic cardiomyopathy. Let's have a closer look to the left ventricle. Report of our experience. Journal of Cardiovascular Magnetic Resonance, 2015, 17, Q74.	1.6	0
99	Evidence From Pacing in Obstructive Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2016, 69, 532.	0.4	0
100	Evidencia del tratamiento con marcapasos en la miocardiopatÃa hipertrófica obstructiva. Revista Espanola De Cardiologia, 2016, 69, 532.	0.6	0